People with type 2 diabetes who take SGLT-2 inhibitors tend to have lower fasting insulin levels than those using other diabetes drugs.

Scientific Claim

In patients with type 2 diabetes, SGLT-2 inhibitor use is associated with lower fasting insulin levels compared to other glucose-lowering drugs (n=32 vs 38, p < 0.05).

Original Statement

“uric acid (Fig. 2C) and insulin levels (Fig. 2D) were significantly lower in the SGLT-2i group compared with the oGLD group.”

From study:Anti-inflammatory effect of SGLT-2 inhibitors via uric acid and insulin

Evidence Quality Assessment

Claim Status

appropriately stated

Study Design Support

Design supports claim

Appropriate Language Strength

association

Can only show association/correlation

Assessment Explanation

Observational study design only supports association. 'Associated with' correctly reflects the evidence.

Evidence from Studies

Supporting (1)

Anti-inflammatory effect of SGLT-2 inhibitors via uric acid and insulin

Cross-Sectional Study

Human

2022 May 3

Contradicting (0)

No contradicting evidence found

Source Study

Anti-inflammatory effect of SGLT-2 inhibitors via uric acid and insulin

Score: 49

DOI: 10.1007/s00018-022-04289-z

Similar Assertions

People with type 2 diabetes who take SGLT-2 inhibitors tend to have lower levels of a key inflammation marker called interleukin-6 than those taking other diabetes medications.

86%

Type 2 diabetes patients taking SGLT-2 inhibitors have lower levels of uric acid in their blood than those on other diabetes medications.

85%